Cargando…
Decreased expression of miR-29 family associated with autoimmune myasthenia gravis
BACKGROUND: Myasthenia gravis (MG) is a rare autoimmune disease mainly mediated by autoantibodies against the acetylcholine receptor (AChR) at the neuromuscular junction. The thymus is the effector organ, and its removal alleviates the symptoms of the disease. In the early-onset form of MG, the thym...
Autores principales: | Cron, Mélanie A., Payet, Cloé A., Fayet, Odessa-Maud, Maillard, Solène, Truffault, Frédérique, Fadel, Elie, Guihaire, Julien, Berrih-Aknin, Sonia, Liston, Adrian, Le Panse, Rozen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7545844/ https://www.ncbi.nlm.nih.gov/pubmed/33032631 http://dx.doi.org/10.1186/s12974-020-01958-3 |
Ejemplares similares
-
Myasthenia Gravis: An Acquired Interferonopathy?
por: Payet, Cloé A., et al.
Publicado: (2022) -
Causes and Consequences of miR-150-5p Dysregulation in Myasthenia Gravis
por: Cron, Mélanie A., et al.
Publicado: (2019) -
Altered expression of fragile X mental retardation-1 (FMR1) in the thymus in autoimmune myasthenia gravis
por: Thomas, Scott, et al.
Publicado: (2021) -
Single-cell mass cytometry on peripheral cells in Myasthenia Gravis identifies dysregulation of innate immune cells
por: Verdier, Julien, et al.
Publicado: (2023) -
Regulatory B cells in myasthenia gravis are differentially affected by therapies
por: Yilmaz, Vuslat, et al.
Publicado: (2018)